🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Shukra Pharmaceuticals Limited SHUKRAPHAR NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.shukrapharmaceuticals.com
Company Profile ↓
₹51.93
+25.37% 1Y
Mkt Cap₹2,273.91 Cr
P/E236.05
P/B20.19
52W High₹51.93
52W Low₹41.42
Book Value₹2.05
EPS (TTM)₹0.22

Company Overview

Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical products in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin and cephalosporin. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016. Shukra Pharmaceuticals Limited was incorporated in 1993 and is based in Ahmedabad, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 24.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 31.7%.

Consistent Profit Growth

Net profit has compounded at 71.1% per year over the last five years.

Healthy Margins

Maintains a net profit margin of 38.9%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.06.

Recent Developments

  • Mar 2026 Revenue of ₹56.73 Cr (+74.1% YoY); net profit ₹22.06 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +74.1%, earnings +130.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR -1.2%, profit CAGR 71.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-1.21%
1 Year:74.08%

Compounded Profit Growth

5 Years:71.06%
1 Year:130.37%

Stock Price Performance

1 Year:+25.37%
6 Months:-
3 Months:-
1 Month:-

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 100% of range
₹41.42 ₹51.93
Price Performance
1Y+25.37%
Valuation vs Sector

P/E of 236.05 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 24.6%.
  • Healthy ROCE of 31.7%.
  • Excellent profit margin of 38.9%.
  • Profit CAGR of 71.1% over 5 years.

CONS

  • Trading at a high P/E of 236.1.
  • Revenue declined at -1.2% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
236.05
Industry PE
41.64
Forward P/E est.
118.03
PEG Ratio
-
Book Value
₹2.05
Price to Book
20.19
P/S
31.97
EV/EBITDA
54.40
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-1.21%
Profit 5Y
71.06%
Revenue (YoY)
74.08%
Earnings (YoY)
130.37%

Profitability & Returns

ROCE
31.67%
ROE
24.55%
ROA
18.78%
Profit Margin
38.88%
Op Margin
44.59%
Gross Margin
72.06%
EPS (Latest Qtr)
₹-
EPS (TTM)
₹0.22

Balance Sheet & Liquidity

Debt/Equity
0.06
Quick Ratio
3.03
Current Ratio
3.63
Debt
₹5.02 Cr
Total Assets
₹117.44 Cr
Current Assets
₹83.81 Cr
Working Capital
₹60.72 Cr

Ownership

Promoter Holding
89.32%
Chg in Prom Hold
-
FII / Inst Holding
0.00%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹2,273.91 Cr
Total Revenue (TTM)
₹56.73 Cr
EBITDA
₹33.32 Cr
Free Cash Flow
₹-11.80 Cr
Operating Cash Flow
₹3.93 Cr
Shares Outstanding
₹43.79 Cr
Gross Margin
72.06%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SHUKRAPHAR Shukra Pharmaceuticals Limited NSEPHARMA 51.93 236.05 ₹2,273.91 Cr 0.00% 31.67% 24.55% -1.21% 71.06%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -13.27 Cr5.39 Cr5.88 Cr39.13 Cr6.32 Cr
Cost of Revenue -1.76 Cr77.03 L2.00 Cr7.13 Cr5.94 Cr
Gross Profit -11.51 Cr4.62 Cr3.87 Cr32.00 Cr38.38 L
Operating Expenses -5.13 Cr4.09 Cr5.10 Cr5.70 Cr69.12 L
Operating Income -6.38 Cr53.16 L-1.23 Cr26.30 Cr-30.74 L
EBITDA -8.78 Cr2.43 Cr1.29 Cr27.95 Cr1.65 Cr
Interest Expense -27.08 L26.81 L28.50 L28.17 L25.83 L
Pretax Income -7.57 Cr1.37 Cr19.84 L26.83 Cr38.15 L
Tax Provision -2.18 Cr34.35 L-2.18 Cr6.47 Cr2.10 Cr
Net Income -5.39 Cr1.03 Cr2.38 Cr20.36 Cr-1.72 Cr
Diluted EPS ------

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -58.83 Cr74.57 Cr32.59 Cr56.73 Cr
Cost of Revenue -45.32 Cr44.49 Cr8.11 Cr15.85 Cr
Gross Profit -13.52 Cr30.09 Cr24.48 Cr40.88 Cr
Operating Expenses -9.99 Cr12.73 Cr14.75 Cr15.58 Cr
Operating Income -3.53 Cr17.35 Cr9.72 Cr25.30 Cr
EBITDA -6.53 Cr22.21 Cr16.94 Cr33.32 Cr
Interest Expense -25.56 L27.63 L59.49 L1.09 Cr
Pretax Income -4.44 Cr19.88 Cr13.34 Cr28.79 Cr
Tax Provision -3.52 L1.35 Cr3.76 Cr6.73 Cr
Net Income -4.41 Cr18.54 Cr9.58 Cr22.06 Cr
Diluted EPS 0.020.140.420.22-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -74.97 Cr77.84 Cr86.77 Cr117.44 Cr
Current Assets -53.07 Cr56.23 Cr65.43 Cr83.81 Cr
Cash & Equivalents -3.97 Cr9.98 Cr12.12 Cr5.98 Cr
Inventory -3.16 Cr2.31 Cr9.95 Cr13.90 Cr
Receivables -30.19 Cr24.51 Cr8.77 Cr22.95 Cr
Total Liabilities -49.67 Cr20.20 Cr23.93 Cr27.59 Cr
Current Liabilities -42.51 Cr14.15 Cr17.28 Cr23.09 Cr
Long Term Debt -3.77 Cr2.66 Cr3.11 Cr3.19 Cr
Total Debt -5.08 Cr3.15 Cr4.18 Cr5.02 Cr
Total Equity -25.30 Cr57.63 Cr62.84 Cr89.85 Cr
Shares Outstanding -7.20 Cr43.79 Cr43.79 Cr43.79 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -3.17 Cr-5.20 Cr7.92 Cr3.93 Cr
Investing Cash Flow --4.43 Cr-1.20 Cr-1.26 Cr-14.14 Cr
Financing Cash Flow -4.94 Cr12.40 Cr-4.52 Cr4.07 Cr
Capital Expenditure --4.49 Cr-1.76 Cr-2.74 Cr-15.73 Cr
Free Cash Flow --1.32 Cr-6.96 Cr5.18 Cr-11.80 Cr
Net Change in Cash -3.68 Cr6.01 Cr2.14 Cr-6.14 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -23.0%40.3%75.1%72.1%
Operating Margin % -6.0%23.3%29.8%44.6%
Net Margin % -7.5%24.9%29.4%38.9%
ROE % -17.4%32.2%15.2%24.6%
ROCE % -10.9%27.2%14.0%26.8%

Shareholding Pattern

Insiders
89.32%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SHUKRAPHAR

Google News Fri, 14 Aug 2026

SHUKRAPHAR Stock Price and Chart — NSE:SHUKRAPHAR - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9uQWhJbG50UEVvdkFiVnpVbVFtWHFPb0RtZjFXOURMblZwd25TT1NmYmN1OFdlcjR1b3k3elZQNnVLTElVekF3dGJqLUVmNUNOTlVtQ0NBYzhUem5KSHlXaw?oc=5" target="_blank">SHUKRAPHAR Stock Price and Chart — NS…

Google News ue, 01 Sep 2026

Technical Analysis of Shukra Pharmaceuticals Ltd. (NSE:SHUKRAPHAR) - TradingView

<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTE1fZlU0VFJBTldFUHN4amZac1h6NFYyVDZDRUpBNWdLb1NxRW90a3ZSS0dmNDF4UUpGcGpINGZ1RnhBTlV2b1JmVHcwMzJ5SVhWb0JZaXcwaFBJZVg5cERYWTgxOHJhUjVfeFlvLUVYOA?oc=5" target="_blank">Technical Analysi…

Google News Sat, 15 Aug 2026

Revenue per share of Shukra Pharmaceuticals Ltd. – NSE:SHUKRAPHAR - TradingView

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNMzBlUy00WV9lZi00bHphbXVQRGZXNWRJd29PSmI5TjhremF3Zm9kVjVOUlNsbW1ZRXJlMUp1cjBSMXpGcGpNaU0xbUVlTThRUThycWt3cHF3YjM5c3hvakttWVQxS2pqNDRzRENVdkN6QkEwelhDZHZNOC16WE4zWl9oR0pqZ0lZNmFwX0…

Google News Sun, 06 Sep 2026

SHUKRA PHARMA RG (SHUKRAPHAR) Fundamental and Financial Data - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiaEFVX3lxTE1HYUJIeTVYblB0bHczTkNrLThmZC1jaDI0OUQxQW9ZSjl1bmVlRnYyTFhpU3lkVWx1cjdtblFiS1UtNWQ2b1lSSzUzZFJvdk0yb1dKZkN3N2VmVkllUUg1d0p4b2hmRzVu?oc=5" target="_blank">SHUKRA PHARMA RG (SHUKRAPHA…

Google News Sat, 15 Aug 2026

Shukra Pharmaceuticals Ltd. Statistics – NSE:SHUKRAPHAR - TradingView

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxOVFI0X3lzQzBWWktuSzZOcTZvdTljdVZsUlMwTzI2cmN2TU95bzJtZGZsUU1MN3B5cE9wb19UZDNtQlN0cmZDU2tmSDZ1T29OQ05tSnpVR3dmckdXUU5US0FvenVjVEVvcWpUdlRJNGlMZXJxVnFvb19XMGZEaDNLLTd6bVdnWU9UNWNoeA…

Google News Sat, 03 Jan 2026

Shukra Pharmaceuticals Ltd. Share Price Today - Shukra Pharmaceuticals Ltd. Stock Price Live NSE/BSE - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQVThlNVdMbmRpX1prTjRRZW5kRFhHNjN5NDFudzVJbDdiVHV5MTdOeXR3SjdyQllEVkVLOVdqT2VHNGhQQzBkNmVUaUl6ejVIVjlWLWRYb0RzUGRIODhMVXBybWE1Y2NTeENaN2x4NjRZS1JJVEtnNE9LaEs2dzBkeFR0U1VhcUNaM1hiUX…

SHUKRAPHAR — Frequently Asked Questions

What is the current share price of Shukra Pharmaceuticals Limited (SHUKRAPHAR)?

As of 2026-09-08 04:53 IST, Shukra Pharmaceuticals Limited (SHUKRAPHAR) trades at ₹51.93 on NSE. Its 52-week range is ₹41.42 to ₹51.93.

What is the market capitalisation of SHUKRAPHAR?

Shukra Pharmaceuticals Limited (SHUKRAPHAR) has a market capitalisation of ₹2,273.91 Cr on NSE.

What is the P/E ratio of SHUKRAPHAR?

SHUKRAPHAR trades at a trailing price-to-earnings (P/E) ratio of 236.05. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 20.19.

What is the return on equity (ROE) of SHUKRAPHAR?

SHUKRAPHAR has a return on equity (ROE) of 24.55%. Its return on capital employed (ROCE) is 31.67%.

Is SHUKRAPHAR a good stock to buy?

This page provides a data-driven analysis of Shukra Pharmaceuticals Limited (SHUKRAPHAR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space